【作者】 宋飞飞；

【导师】 杨世忠；

【作者基本信息】 长春中医药大学 ， 中医内科学， 2008， 硕士

【摘要】 目的:观察肠康饮(CKY)作用于UC大鼠的疗效及其机制。方法:将70只健康Wistar大鼠随机分成6组,A组:正常对照组10只、B组:模型对照组12只、C组:CKY低剂量组12只、D组:CKY中剂量组12只、E组:CKY高剂量组12只、F组:SASP对照组12只。A组注入0.25m10.9%生理盐水灌肠,其余5组注入100mg/kg TNBS加50%乙醇0.25ml混合试剂灌肠。造模后第二天,C、D、E组分别按CKY11g/kg、22g/kg及44g/kg体重灌胃,F组按0.5g/kg体重灌胃,A、B组给予蒸馏水按10ml/kg体重灌胃。每日一次,灌胃体积均为10mL/kg,连续21天后按DAI标准评分、结肠组织损伤大体形态学评分和病理组织学评分。测定结肠组织中超氧化物歧化酶(SOD)活性和诱导型一氧化氮合酶(iNOS)表达。结果:大鼠DAI评分、结肠组织损伤大体形态学评分和病理组织学评分、肠组织SOD活性及iNOS表达,E组与B组比较有极显著性差异(P＜0.01);D、F组与B组比较有显著性差异(P＜0.05);B、C组与A组比较有极显著性差异(P＜0.01);D、F组与A组比较有显著性差异(P＜0.05)。结论:CKY是治疗UC大鼠模型的有效药物。E组疗效较F组为优。CKY可能是通过增强肠组织中SOD活性和降低iNOS表达达到治疗目的。更多还原

【Abstract】 Objective To find the effect and mechanism of CKY to the ulcerative colitis rat model.Methods Totally 70 healthy Wistar rats were divided into 6 groups by random.Group A(10 rats):normal control group.Group B(12 rats):model control group.Group C(12 rats): CKY low dose group.Group D(12 rats):CKY moderate dose group.Group E(12 rats):CKY high dose group.Group F(12 rats):SASP control group group.The rats of Group A were made with 0.25mL of 0.9%normal saline enemal.The others groups were made with 100mg/kg TNBS plus 0.25mL mixing reagent.The second day after the rat model establishment,the administration by stomach of CKY as 11g/kg,22g/kg,44g/kg were performed to rats in Group C,D,E.The administration by stomach of CKY were performed as 11ml/kg once daily.The DAI standard score and morphology and pathohistology score of colon injury were performed after twenty one days.The activity of superoxide dismutase (SOD) and the expression of induced nitricoxide synthase(iNOS) in colon were determined.Results Extreme significant difference(P＜0.01)were found between Group E and B on the DAI standard score and morphology and pathohistology score of colon injury and the activity of SOD and the expression of iNOS in colon.Significant difference(P＜0.05) were found among Group D,F,B.Extreme significant difference(P＜0.01) were found between Group B,C and A.Significant difference(P＜0.05) were found between Group D,F and A.Conclusion CKY is an active drug to the ulcerative colitis rat model.The therapeutic effect in Group E is superior to that of Group F.The therapeutic mechanism of CKY may enhance the activity of SOD and decrease the expression of iNOS in colon.更多还原